TNS1 Antibody

What is TNS1 and what are its key functions in cellular processes?

TNS1 (Tensin 1) is a multidomain protein that interacts with the actin cytoskeleton, binds β1-integrin, and serves as a scaffold for adhesion-related signaling . The protein is encoded by the gene TNS1 in humans and may also be known by several aliases including TNS, MST091, MST122, MST127, MSTP091, and Matrix-remodelling-associated protein 6 .

TNS1 has several critical cellular functions:

• Essential for myofibroblast differentiation and myofibroblast-mediated extracellular matrix deposition

• Involved in fibrillar adhesion formation

• Enhances RHOA activation in the presence of DLC1

• Plays a role in cell polarization and migration

• May be involved in cartilage development and in linking signal transduction pathways to the cytoskeleton

The expected protein mass is 185.7 kDa, though there are two reported isoforms that may display different molecular weights when analyzed by Western blotting .

TNS1 expression is strongly induced during myofibroblast differentiation. Research has shown that:

• Basal expression of TNS1 under serum-starved conditions is very low in normal human lung fibroblasts (HLFs)

• Treatment with TGF-β strongly induces TNS1 protein expression, with similar kinetics to the myofibroblast marker gene, smooth muscle α-actin (ACTA2)

• The induction of TNS1 by TGF-β appears to be, at least in part, transcriptionally regulated, as evidenced by increased TNS1 mRNA levels at 6 and 24 hours post-TGF-β stimulation

• TNS1 expression is also observed to increase in fibrotic lung tissue, suggesting its role in fibrotic processes

This expression pattern makes TNS1 antibodies valuable tools for studying myofibroblast differentiation and tissue fibrosis.

How can researchers distinguish between different phosphorylation states of TNS1?

TNS1 is extensively phosphorylated at tyrosine and serine/threonine sites in response to integrin activation by the extracellular matrix . When performing Western blot analysis:

• Researchers may observe a doublet signal for TNS1 under TGF-β treatment for extended periods

• The appearance of a second, higher apparent molecular weight band could represent an electrophoretic mobility shift due to increased phosphorylation

• Specific phosphorylation sites, such as Y1404, have been reported to increase in response to TGF-β stimulation

To distinguish between phosphorylation states:

• Use phospho-specific TNS1 antibodies, such as those targeting phosphorylated Tyr1326

• Perform lambda phosphatase treatment of lysates to confirm phosphorylation-dependent mobility shifts

• Consider employing 2D gel electrophoresis to separate different phosphorylated species

What signaling pathways regulate TNS1 expression and how can this be studied using antibodies?

Research has revealed that TNS1 expression is regulated through several intricate signaling pathways:

• TGF-β/Smad-independent pathway:

  • TGF-β induces TNS1 expression via the TGF-β type I receptor (activin receptor-like kinase 5)

  • This signaling requires the TGF-β type I receptor but is independent of Smad2/3 signaling

  • The small-molecule inhibitor SB431542 fully inhibits TGF-β-induced TNS1 expression

• ROCK/actin/MKL1/SRF pathway:

  • TGF-β-induced TNS1 expression depends on Rho-associated protein kinase (ROCK) activation

  • Actin polymerization is required for TNS1 induction by TGF-β

  • The MKL1/SRF transcriptional complex directly regulates TNS1 expression

  • ROCK inhibitor Y27632, actin polymerization disruptors latrunculin B, and formin homology 2 domain inhibitors all inhibit TGF-β-induced TNS1 expression

• Alternative induction pathways:

  • Jasplakinolide, an inducer of actin polymerization, reliably induces TNS1 expression

  • α-thrombin stimulation induces TNS1 expression in an MKL1/SRF-dependent manner

To study these pathways:

• Use TNS1 antibodies in conjunction with pathway inhibitors to assess expression changes by Western blot

• Combine with phospho-specific antibodies against pathway components to track signaling activation

• Employ chromatin immunoprecipitation (ChIP) assays to study MKL1/SRF binding to the TNS1 promoter

What is the role of TNS1 in cystic kidney disease and how can antibodies help elucidate this mechanism?

TNS1 knockout mice develop cystic kidneys and die from renal failure . Research using TNS1-knockout MDCK cells in 3D culture systems has revealed:

• Wild-type MDCK cells form cysts with a single lumen, while TNS1-knockout cysts contain multiple lumens

• TNS1-knockout cells show upregulated Mek/Erk activities

• The multiple lumen phenotype and Mek/Erk hyperactivities can be rescued by re-expression of wild-type TNS1

• TNS1 mutants lacking fragments essential for cell-cell junction localization cannot rescue the phenotype

• Mek inhibitor treatments restore the multiple lumens back to single lumen cysts

• Mek/Erk hyperactivities are also detected in TNS1-knockout mouse kidneys

• Treatment with the Mek inhibitor trametinib significantly reduces the levels of interstitial infiltrates, fibrosis, and dilated tubules in TNS1-knockout kidneys

TNS1 antibodies can help elucidate this mechanism by:

• Localizing TNS1 at cell-cell junctions and other subcellular compartments using immunofluorescence

• Monitoring TNS1 expression in various kidney disease models using immunohistochemistry

• Assessing TNS1 interactions with signaling components of the Mek/Erk pathway through co-immunoprecipitation

• Evaluating therapeutic responses to Mek inhibitors by examining TNS1 and phospho-Erk levels

What are the optimal conditions for using TNS1 antibodies in immunofluorescence studies?

For optimal immunofluorescence staining with TNS1 antibodies, consider the following evidence-based recommendations:

• Fixation and permeabilization:

  • Standard paraformaldehyde fixation (4%) for 15-20 minutes at room temperature is typically effective

  • For visualizing focal and fibrillar adhesions, permeabilization with 0.1% Triton X-100 is recommended

• Antibody dilutions:

  • Primary TNS1 antibodies are typically used at dilutions between 1:100 to 1:500

  • Secondary antibodies should be appropriately matched to the host species of the primary antibody

• Co-staining considerations:

  • For focal adhesion studies, co-staining with markers such as paxillin or vinculin can provide valuable context

  • For fibrillar adhesion visualization, co-staining with fibronectin is informative

• Imaging parameters:

  • High-resolution imaging (60× magnification or higher) is recommended for clear visualization of adhesion structures

  • Z-stack imaging may be necessary to fully capture the three-dimensional nature of adhesion structures

• Quantitative analysis:

  • To determine average focal or fibrillar adhesion lengths, measure at least 15 adhesion lengths per image

  • To determine average number of focal or fibrillar adhesions, count adhesions per image and normalize to cell count

How can researchers effectively analyze TNS1's role in fibrillar adhesion formation and matrix assembly?

TNS1 is a critical component of specialized cell adhesions (fibrillar adhesions) that are essential for the formation of a fibrillar fibronectin matrix . To effectively analyze TNS1's role in these processes:

• Fibronectin Assembly Assay:

  • Seed cells on coverslips and culture to allow for matrix deposition

  • Fix cells and stain with antibodies against TNS1 and fibronectin

  • Analyze the co-localization of TNS1 with newly formed fibronectin fibrils

  • Quantify fibril length, density, and orientation

• TNS1 Knockdown Studies:

  • Use siRNA-mediated knockdown of TNS1 with appropriate controls

  • Verify knockdown efficiency using Western blot with TNS1 antibodies

  • Assess the impact on fibrillar adhesion formation and extracellular matrix assembly

  • Small-interfering RNA–mediated knockdown of TNS1 has been shown to disrupt TGF-β–induced myofibroblast differentiation without affecting TGF-β/Smad signaling

• Rescue Experiments:

  • Re-express wild-type TNS1 or specific domain mutants in TNS1-knockdown or knockout cells

  • Use TNS1 antibodies to confirm expression levels and localization

  • Evaluate restoration of fibrillar adhesions and matrix assembly functions

• Phosphorylation Analysis:

  • Loss of TNS1 results in disruption of focal adhesion kinase phosphorylation

  • Use phospho-specific antibodies against FAK in conjunction with TNS1 antibodies to monitor this relationship

What controls should be included when using TNS1 antibodies for experimental validation?

Proper controls are essential for ensuring the reliability and validity of experiments using TNS1 antibodies:

• Positive Controls:

  • Cell lines with confirmed TNS1 expression (e.g., TGF-β-treated human lung fibroblasts)

  • Recombinant TNS1 protein for Western blot positive control

  • TNS1-transfected cells (e.g., TNS1-transfected 293T cells)

• Negative Controls:

  • TNS1 knockout or knockdown cells or tissues

  • Non-transfected cells for recombinant expression systems

  • Primary antibody omission control for immunostaining

  • Isotype control antibodies

• Specificity Validation:

  • Blocking peptide competition assays to confirm antibody specificity

  • Multiple antibodies targeting different epitopes of TNS1 to confirm findings

  • Testing in multiple species if cross-reactivity is claimed

• Functional Validation:

  • Demonstrate expected changes in TNS1 levels with stimuli known to induce expression (e.g., TGF-β, jasplakinolide, α-thrombin)

  • Show expected subcellular localization (e.g., focal adhesions, fibrillar adhesions)

  • Verify functional outcomes of TNS1 manipulation (e.g., effects on fibronectin assembly)

How can researchers troubleshoot non-specific binding when using TNS1 antibodies?

Non-specific binding can complicate the interpretation of results when using TNS1 antibodies. Here are evidence-based approaches to address this issue:

• Western Blot Optimization:

  • The predicted molecular weight of TNS1 is 185.7 kDa, but researchers have observed bands at various weights including 111 kDa

  • Use longer SDS-PAGE gels with appropriate molecular weight markers to better resolve high molecular weight proteins

  • Optimize blocking conditions (BSA vs. milk) as TNS1 antibodies may perform differently with different blocking agents

  • Increase washing stringency and duration to reduce background

• Immunostaining Improvements:

  • Pre-adsorb antibodies with cell/tissue lysates from TNS1 knockout systems if available

  • Optimize antibody concentration by performing titration experiments

  • Include additional blocking steps with normal serum from the secondary antibody host species

  • Consider using fluorophore-conjugated primary antibodies to eliminate secondary antibody cross-reactivity

• Specificity Confirmation:

  • Use multiple TNS1 antibodies targeting different epitopes and compare staining patterns

  • Implement peptide competition assays using the immunizing peptide

  • Perform parallel staining with TNS1 knockout/knockdown samples as negative controls

• Technical Considerations:

  • For phospho-specific TNS1 antibodies (such as phospho-Tyr1326), include phosphatase inhibitors in all sample preparation steps

  • Consider the fixation method, as certain epitopes may be masked by specific fixatives

  • For co-immunoprecipitation experiments, optimize lysis conditions to preserve protein-protein interactions

What are the important considerations when studying different TNS1 isoforms with antibodies?

TNS1 has two reported isoforms , which presents challenges when designing experiments to study specific isoform functions:

• Isoform-Specific Detection:

  • Choose antibodies with epitopes that can distinguish between isoforms

  • Confirm the targeted region of the antibody (e.g., N-terminal, C-terminal, or internal domains)

  • Antibodies targeting amino acids 1-400 or 1-350 may detect multiple isoforms

• Expression Analysis:

  • Use high-resolution SDS-PAGE to separate isoforms that may have similar molecular weights

  • Consider 2D gel electrophoresis to separate isoforms with post-translational modifications

  • Implement RT-PCR with isoform-specific primers to correlate protein detection with mRNA expression

• Functional Studies:

  • Design isoform-specific knockdown approaches (targeting untranslated regions)

  • Create expression constructs for individual isoforms for rescue experiments

  • Consider domain-specific functionality when interpreting results (e.g., different isoforms may have altered binding partners or subcellular localization)

• Post-Translational Modifications:

  • Be aware that TNS1 can appear as a doublet in Western blots due to phosphorylation

  • Phosphorylation at sites like Y1404 increases in response to TGF-β stimulation

  • Use phosphatase treatments to distinguish between phosphorylation states and isoforms

How can researchers optimize immunohistochemical detection of TNS1 in different tissue samples?

Optimizing immunohistochemical detection of TNS1 requires consideration of tissue-specific factors:

• Tissue Processing and Antigen Retrieval:

  • Paraformaldehyde-fixed, paraffin-embedded tissues typically require heat-induced epitope retrieval (HIER)

  • Citrate buffer (pH 6.0) or Tris-EDTA buffer (pH 9.0) are commonly used for HIER with TNS1 antibodies

  • Optimization of retrieval time and temperature may be necessary for different tissue types

• Antibody Selection and Optimization:

  • For TNS1 detection in lung tissue, antibodies validated for immunohistochemistry-paraffin (IHC-p) applications are recommended

  • For kidney tissues, especially when studying cystic diseases, antibodies that detect the junctional localization of TNS1 are critical

  • Titrate antibody concentrations for each tissue type to determine optimal signal-to-noise ratio

• Detection Systems:

  • Horseradish peroxidase-conjugated secondary antibodies with DAB substrate are commonly used for TNS1 visualization in tissues

  • For co-localization studies, consider fluorescent secondary antibodies and confocal microscopy

  • Amplification systems (e.g., tyramide signal amplification) may be beneficial for detecting low-abundance TNS1 in certain tissues

• Tissue-Specific Considerations:

  • In lung tissue, TNS1 expression increases during fibrosis and myofibroblast activation

  • In kidney tissue, TNS1 localization at cell-cell junctions is critical for normal function

  • Compare staining patterns between normal and diseased tissues to identify pathology-associated changes in TNS1 expression or localization